4-(3-{[(Carboxy)propyl]oxy}-4-methoxyphenyl)-2-pyrrolidinone | 104806-85-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-(3-{[(Carboxy)propyl]oxy}-4-methoxyphenyl)-2-pyrrolidinone
• 英文别名: 4-[2-Methoxy-5-(5-oxo-pyrrolidin-3-yl)-phenoxy]-butyric acid；4-[2-methoxy-5-(5-oxopyrrolidin-3-yl)phenoxy]butanoic acid
• CAS: 104806-85-1
• 化学式: C₁₅H₁₉NO₅
• 分子量: 293.32
• InChiKey: VQDAWOMOPCBVQU-UHFFFAOYSA-N

物化性质

• 沸点：
  572.2±50.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(3-{[(Carboxy)propyl]oxy}-4-methoxyphenyl)-2-pyrrolidinone 、 N-甲基环己胺 在 三乙胺 、 氯甲酸异丁酯 作用下， 生成 4-[3-({[(N-Cyclohexyl-N-methylamino)carbonyl]propyl}oxy)-4-methoxyphenyl]-2-pyrrolidinone
  参考文献：
  名称：

  Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogs

  摘要：

  Rolipram [(R,S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone] has been shown to inhibit selectively the cAMP phosphodiesterase (PDE) of vascular smooth muscle. In order to further explore the structural requirements for selective PDE inhibition, we synthesized a series of rolipram derivatives differently substituted either at the pyrrolidinone or at the aromatic ring. Among these compounds, rolipram was the most active compound. Semirigid analogues were prepared and used for an evaluation of the active conformation of rolipram. Structural comparison with two other potent and chemically different smooth muscle cAMP-PDE inhibitors, trequinsin and Ro 20-1724, allows us to propose a first topological model of the smooth muscle cAMP-PDE pharmacophore.

  DOI：

  10.1021/jm00127a009
• 作为产物：
  描述：

  4-(3-hydroxy-4-methoxyphenyl)-pyrrolidin-2-one 在 sodium hydroxide 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 12.5h， 生成 4-(3-{[(Carboxy)propyl]oxy}-4-methoxyphenyl)-2-pyrrolidinone
  参考文献：
  名称：

  Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogs

  摘要：

  Rolipram [(R,S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone] has been shown to inhibit selectively the cAMP phosphodiesterase (PDE) of vascular smooth muscle. In order to further explore the structural requirements for selective PDE inhibition, we synthesized a series of rolipram derivatives differently substituted either at the pyrrolidinone or at the aromatic ring. Among these compounds, rolipram was the most active compound. Semirigid analogues were prepared and used for an evaluation of the active conformation of rolipram. Structural comparison with two other potent and chemically different smooth muscle cAMP-PDE inhibitors, trequinsin and Ro 20-1724, allows us to propose a first topological model of the smooth muscle cAMP-PDE pharmacophore.

  DOI：

  10.1021/jm00127a009

文献信息

• MARIVET, MICHEL C.;BOURGUIGNON, JEAN-JACQUES;LUGNIER, CLAIRE;MANN, ANDRE;+, J. MED. CHEM., 32,(1989) N, C. 1450-1457
  作者：MARIVET, MICHEL C.、BOURGUIGNON, JEAN-JACQUES、LUGNIER, CLAIRE、MANN, ANDRE、+

  DOI：——

  日期：——
• Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogs
  作者：Michel C. Marivet、Jean Jacques Bourguignon、Claire Lugnier、Andre Mann、Jean Claude Stoclet、Camille Georges Wermuth

  DOI：10.1021/jm00127a009

  日期：1989.7

  Rolipram [(R,S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone] has been shown to inhibit selectively the cAMP phosphodiesterase (PDE) of vascular smooth muscle. In order to further explore the structural requirements for selective PDE inhibition, we synthesized a series of rolipram derivatives differently substituted either at the pyrrolidinone or at the aromatic ring. Among these compounds, rolipram was the most active compound. Semirigid analogues were prepared and used for an evaluation of the active conformation of rolipram. Structural comparison with two other potent and chemically different smooth muscle cAMP-PDE inhibitors, trequinsin and Ro 20-1724, allows us to propose a first topological model of the smooth muscle cAMP-PDE pharmacophore.